Replies to post #962 on Vascular Biogenics Ltd (VBLT)

[Oren1976]

If they are smart they charge only 50000 . The days of expensive drugs in cancer is close to an end. Remember it's combination drug also being ethic is not bad.

[Valueinvestor12]

gr8db8 This is from Seeking Alpha:

VB-111 reaching the market in recurrent GBM market indication and expect it to be priced in the range of $150K-$200K per year (average wholesale price, AWP). Assuming US launch in 2018 and peak 25% market penetration, we estimate about $160 million risk-adjusted US revenue (after 2% royalties payable to Crucell) in 2023.He eatimated that 74,000 people in the USA having rgbm